Doctors association slams US for pressuring India on pharma
A Geneva-based non-profit doctors association has criticized the US and its pharma lobby for exerting pressure on India for its patent laws
Washington: A Geneva-based non-profit doctors association has criticized the US and its pharma lobby for exerting pressure on India for its patent laws, saying such actions undermine the global trading system.
“Every country has the right to take steps to increase access to medicines and implement a patent system in line with its public health needs. We strongly object to the pressure exerted by the US on developing countries, including India, for using legal flexibilities to protect public health,” Rohit Malpani of the Doctors Without Borders told the US International Trade Commission yesterday.
USITC has conducted a hearing this week in connection with its investigation “Trade, Investment, and Industrial Policies in India: Effects on the US Economy”.
“India’s measures are fully compliant with global trade rules and with the laws of India. These attacks undermine the global trading system as well as the independence of the Indian judiciary, which was responsible for the decisions under discussion today,” Malpani told the USITC members.
The measures India has implemented to safeguard public health are of critical importance to protect the health of millions of people across the world. India has been nicknamed the “pharmacy to the developing world” in recognition of this fact, he said.
“Losing this ‘pharmacy’ would be devastating for patients and for treatment providers,” he said and urged USITC to evaluate the decisions made by the Indian government under international trade rules taking in to consideration its impact on public health.
Taking to task the strong US pharma lobby, which in the past one year has launched a campaign against India, the Doctors Without Border representatives said relying on high prices for medicines backed up by intellectual property monopolies is a flawed paradigm to pay for medical innovation.
“It creates both access problems due to high prices – as we have seen – and at the same time it does not stimulate innovation for many of the diseases affecting people in developing countries, where patients have limited purchasing power and the private sector sees no incentive,” Malpani said.
“Today, we basically have a trade between innovation and access. If you have wide access, says the industry, you aren’t supporting innovation,” he said.
“Seeking greater intellectual property norms in countries like India that are the source of access for millions around the world, not only does little for innovation but it perpetuates a failed business model,” Malpani said.
“Instead of aggressively pushing governments, such as India, to ignore its legal rights under international trade rules to ensure affordable medicine prices, the US government should work with India and other countries, to invest in and develop new models of innovation that promote both innovation and access,” he said.